Species predicted to react based on 100% sequence homology:Human, Mouse
Specificity / Sensitivity
Phospho-Tpl2 (Ser400) Antibody detects transfected Tpl2 only when phosphorylated at Ser400. This antibody does not cross-react with other phosphorylated MAP kinase kinase kinases.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a mixture synthetic phosphorylated peptides corresponding to residues surrounding Ser400 of human, mouse and rat Tpl2. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Tpl2 (tumor progression locus 2), also known as COT (cancer osaka thyroid), is a serine/threonine kinase expressed primarily in hematopoietic tissues, lung and liver (1). Over-expression of Tpl2 potentiates MAP kinase pathways through MEK1 and SEK1, as well as through MKK6 and MEK5 (2,3). Tpl2 is also engaged in NF-κB activation through NF-κB inducing kinase (NIK), or by inducing phosphorylation and degradation of the NF-κB precusor, p105 NF-κB1 (4,5). Ser400 of Tpl2 is phosphorylated in an Akt-dependent manner. This phosphorylation is required for Tpl2-induced NF-κB-dependent transcription (6). Tpl2 also activates caspase-3 by promoting the assembly of a protein complex of Apaf1 (apoptotic protease-activating factor 1), caspase-9, Tpl2, adaptor protein Tvl1 and procaspase-3 (7).